Longeveron (LGVN) Current Assets (2021 - 2026)
Longeveron (LGVN) posted quarterly Current Assets of $16.9 million for Q1 2026, up 10.34% year-over-year from $15.3 million in Q1 2025, and up 209.21% quarter-over-quarter from $5.5 million in Q4 2025.
Longeveron (LGVN) Current Assets (2021 - 2026) Analysis & Trends
Longeveron's Current Assets history runs 6 years deep, the most recent figure standing at $16.9 million for Q1 2026.
- In Q1 2026, Current Assets rose 10.34% year-over-year to $16.9 million; the TTM figure through Mar 2026 stood at $16.9 million (up 10.34% YoY), while the FY2025 annual figure was $5.5 million, down 72.22% from the prior year.
- Current Assets for Q1 2026 stood at $16.9 million, up from $5.5 million in the prior quarter.
- The five-year high for Current Assets was $23.8 million in Q3 2024, with the low at $3.8 million in Q1 2024.
- The 5-year median for Current Assets is $12.3 million (2024), against an average of $12.6 million.
- Peak annual rise in Current Assets reached 371.19% in 2024, while the deepest fall reached 74.73% in 2024.
- Longeveron's Current Assets stood at $20.3 million in 2022, then slumped by 71.16% to $5.8 million in 2023, then surged by 235.57% to $19.6 million in 2024, then sank by 72.22% to $5.5 million in 2025, then surged by 209.21% to $16.9 million in 2026.
- Business Quant data shows LGVN's Current Assets at $16.9 million in Q1 2026, $5.5 million in Q4 2025, and $10.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | 11.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.32 Mn |
| Mar 31, 2026 | 16.86 Mn |
| Dec 31, 2025 | 5.45 Mn |
| Sep 30, 2025 | 10.34 Mn |
| Jun 30, 2025 | 11.27 Mn |
| Mar 31, 2025 | 15.28 Mn |
| Dec 31, 2024 | 19.62 Mn |
| Sep 30, 2024 | 23.77 Mn |
| Jun 30, 2024 | 13.41 Mn |
| Mar 31, 2024 | 3.76 Mn |
| Dec 31, 2023 | 5.85 Mn |
| Sep 30, 2023 | 5.04 Mn |
| Jun 30, 2023 | 10.29 Mn |
| Mar 31, 2023 | 14.87 Mn |
| Dec 31, 2022 | 20.28 Mn |
| Dec 31, 2021 | 35.38 Mn |